Resources with keywords: flavivirus

CDC ArboNET and Florida health bulletins confirmed ongoing domestic Zika surveillance, recording 5 travel-associated cases nationally with zero local vector transmission in 2026. Public health advisories emphasize aggressive differential testing in febrile patients. Diagnostic laboratories are alerted to extensive serological IgM cross-reactivity between Zika and Dengue viruses, which complicates antibody confirmation. Clinicians must order molecular RT-PCR on serum and urine to assess fetal microcephaly risks. Diagnostic specimen processing must be performed within certified Class II Biosafety Cabinets under BSL-2 containment.

Global incidence of dengue in 2024 has been the highest on record for this calendar year; the Americas are reporting record-breaking numbers of infections, infections are more common in the US as well.